Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
50.67
-0.92 (-1.78%)
Oct 21, 2025, 4:00 PM EDT - Market closed
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $64, which forecasts a 26.31% increase in the stock price over the next year. The lowest target is $63 and the highest is $65.
Price Target: $64 (+26.31%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 2 |
| Hold | 2 | 2 | 2 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $40 → $65 | Hold → Buy | Upgrades | $40 → $65 | +28.28% | Oct 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +24.33% | Sep 30, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $36 → $40 | Hold | Maintains | $36 → $40 | -21.06% | Aug 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $42 → $46 | Buy | Maintains | $42 → $46 | -9.22% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $36 | Hold | Reiterates | $36 | -28.95% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
706.24M
from 661.82M
Increased by 6.71%
Revenue Next Year
845.65M
from 706.24M
Increased by 19.74%
EPS This Year
2.27
from 1.32
Increased by 71.80%
EPS Next Year
2.49
from 2.27
Increased by 9.60%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 732.9M | 886.0M | |||
| Avg | 706.2M | 845.7M | |||
| Low | 671.3M | 789.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.7% | 25.5% | |||
| Avg | 6.7% | 19.7% | |||
| Low | 1.4% | 11.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.43 | 2.82 | |||
| Avg | 2.27 | 2.49 | |||
| Low | 2.12 | 2.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 83.7% | 24.5% | |||
| Avg | 71.8% | 9.6% | |||
| Low | 60.4% | -7.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.